Sacubitril/Valsartan Improves Left Atrial and Left Atrial Appendage Function in Patients With Atrial Fibrillation and in Pressure Overload-Induced Mice
LCZ696 (sacubitril/valsartan) is an angiotensin receptor-neprilysin inhibitor and has shown beneficial effects in patients with heart failure. However, whether LCZ696 protects against left atrial (LA) and LA appendage (LAA) dysfunction is still unclear. The present study aimed to assess the efficacy...
Main Authors: | Ya Suo, Meng Yuan, Hongmin Li, Yue Zhang, Ying Li, Huaying Fu, Fei Han, Changhui Ma, Yuanyuan Wang, Qiankun Bao, Guangping Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-10-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2019.01285/full |
Similar Items
-
Percutaneous left atrial appendage closure using the LAmbre device in patients with atrial fibrillation and left atrial appendage thrombus
by: Lu-Shen Jin, et al.
Published: (2022-11-01) -
Overcoming barriers for left atrial appendage thrombus: a systematic review of left atrial appendage closure
by: Zixi Zhang, et al.
Published: (2024-03-01) -
The Left Atrial Appendage and Atrial Fibrillation—A Contemporary Review
by: Ralf Martz Sulague, et al.
Published: (2023-11-01) -
Left Atrial Appendage Occlusion for Stroke Prevention in Nonvalvular Atrial Fibrillation
by: Fareed Moses S. Collado, et al.
Published: (2021-11-01) -
Risk factors of left atrial appendage thrombus in patients with non-valvular atrial fibrillation
by: Liu Yaowu, et al.
Published: (2021-03-01)